Gallbladder Neoplasms clinical trials
The registry lists 301 studies for Gallbladder Neoplasms across more than 10 countries. 65 are recruiting or about to start. 97 of them are mainly about Gallbladder Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.
Get an email when these change. Save the Gallbladder Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Cancer Institute (NCI) (28) · Memorial Sloan Kettering Cancer Center (7) · Shanghai Jiao Tong University School of Medicine (6) · M.D. Anderson Cancer Center (5) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (5) · Alliance for Clinical Trials in Oncology (5) · Mayo Clinic (5) · Yonsei University (4)
What is being tested here
Drugs under test in Gallbladder Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Lenvatinib | 3 | 0 | 5 |
| Gemcitabine | 2 | 8 | 35 |
| Cisplatin | 2 | 4 | 17 |
| Albumin-Bound Paclitaxel | 2 | 0 | 4 |
| Paclitaxel | 2 | 0 | 4 |
| Oxaliplatin | 1 | 4 | 17 |
| Fluorouracil | 1 | 2 | 11 |
| Pembrolizumab | 1 | 2 | 6 |
| Trastuzumab | 1 | 1 | 3 |
| Rilvegostomig | 1 | 2 | 2 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 9 open · Immune checkpoint inhibitors 9 open · Antimetabolites 4 open · Antimitotic agents 2 open · Angiogenesis inhibitors 5
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Aug 2027A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) · Phase 3 · Compass Therapeutics
- Oct 2027A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer · Phase 3 · J-Pharma Co., Ltd.
- Nov 2027Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction · Phase 3 · Erasmus Medical Center
- Nov 2026A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation · Arvinas Inc.
- Dec 2026Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Dec 2026Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types · University of Florida
- Dec 2026The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · PMV Pharmaceuticals, Inc
- Dec 2026STALL vs Sole Local Wound Infiltration in Laparoscopic Cholecystectomy · Helsinki University Central Hospital
- Dec 2026Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer · Tianjin Medical University Cancer Institute and Hospital
- Dec 2026Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer · First Affiliated Hospital of Zhejiang University
Who these studies take
Of the 43 Gallbladder Neoplasms studies recruiting now, 24 (56%) set no upper age limit and 8 (19%) stop at 75 or younger. 4 (9%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (9%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (2%) | 1 (2%) |
| 18 | 41 (95%) | 41 (95%) |
| 30 | 43 (100%) | 43 (100%) |
| 40 | 43 (100%) | 43 (100%) |
| 50 | 43 (100%) | 43 (100%) |
| 65 | 43 (100%) | 43 (100%) |
| 75 | 40 (93%) | 40 (93%) |
| 85 | 31 (72%) | 31 (72%) |
Across all 301 studies, recruiting or not: 12% stop at 75 or younger and 1% at 65; 9% take children; 1% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Gallbladder Neoplasms studies take
Of 43 phase 2 interventional studies under Gallbladder Neoplasms, half reached primary completion within 39 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 43 mo29–53 · 13 studies | — | — |
| Phase 2 | 39 mo32–54 · 43 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 12, 2026.
Stopped1
- Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract CancerSuspendedOct 20, 2026NCT07146646
Newly registered2
Studies
Recruiting first, then most recently updated. Showing 50 of 301. Browse all 301 → or search them.
- Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNot yet recruitingNCT07793253Phase 21 country
- Distance-Based Exercise to Preserve Function and Prevent DisabilityRecruitingNCT07059884Not applicable1 country
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Phase 211 countries
- Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract CancerNot yet recruitingNCT07916844Phase 31 country
- Study of ACC-1898 in Adult Participants With Advanced Solid TumorsNot yet recruitingNCT07252661Phase 1
- Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerRecruitingNCT06282575Phase 325 countries
- Incidental Gallbladder Carcinoma :Incidence and Clinical Significance in Specimens From Routine Cholecystectomies in Sohag LocalityRecruitingNCT078858001 country
- Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsRecruitingNCT06239194Phase 1/21 country
- STALL vs Sole Local Wound Infiltration in Laparoscopic CholecystectomyRecruitingNCT06123117Not applicable1 country
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)RecruitingNCT04585750Phase 1/29 countries
- A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCsRecruitingNCT06423170Phase 21 country
- A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract CancerRecruitingNCT07265674Phase 31 country
- A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)RecruitingNCT07221253Phase 319 countries
- DESTINY-PANTUMOUR04RecruitingNCT071240001 country
- Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaRecruitingNCT07780838Phase 21 country
- AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder CancerNot yet recruitingNCT07767994Phase 2
- Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal MetastasesRecruitingNCT05285358Phase 11 country
- IKS04 Regimen in Advanced Solid Tumors That Express CA242Not yet recruitingNCT07738939Phase 11 country
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesRecruitingNCT05000294Phase 1/21 country
- Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)RecruitingNCT06101277Not applicable1 country
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II StudyRecruitingNCT07636824Phase 21 country
- Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract CancerRecruitingNCT07641036Phase 1/21 country
- A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.Not yet recruitingNCT07623642Phase 21 country
- Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract CancerRecruitingNCT07614061Phase 11 country
- To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid TumorsRecruitingNCT07594964Phase 11 country
- Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder CancerRecruitingNCT06591650Phase 21 country
- Outcomes After Liver and Biliary Resection at a High-Volume CenterNot yet recruitingNCT075568351 country
- TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World CohortNot yet recruitingNCT074544861 country
- Virtual Reality for GI Cancer Pain to Improve Patient Reported OutcomesRecruitingNCT04907643Not applicable1 country
- EULAT Eradicate GBCRecruitingNCT061927195 countries
- Prospective Evaluation of 68Ga-FAPI PET in Biliary CancersRecruitingNCT073378501 country
- Target-specific immunoPET Imaging of Digestive System CarcinomaRecruitingNCT06715839Not applicable1 country
- Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder CancerEnrolling by invitationNCT07310069Phase 21 country
- A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract CancerNot yet recruitingNCT07269158Phase 1/21 country
- DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsRecruitingNCT05786716Phase 2/31 country
- A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers ScreeningRecruitingNCT071769621 country
- Robotic-assisted Contra Open Resection for Suspected or Confirmed Gallbladder Cancer (ROBOCOP)RecruitingNCT06246448Not applicable1 country
- Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract CancerRecruitingNCT07025174Phase 21 country
- Bile Omics for Diagnosing Indeterminate Biliary StricturesRecruitingNCT070078321 country
- Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for CancerNot yet recruitingNCT06999512Phase 2/31 country
- Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)Enrolling by invitationNCT06963060Phase 21 country
- Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)RecruitingNCT06712420Phase 31 country
- Radiation Therapy in Unresectable Gall Bladder CancerRecruitingNCT06214572Phase 2/31 country
- Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaEnrolling by invitationNCT06901622Phase 21 country
- Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder CancerRecruitingNCT06852287Phase 21 country
- Proteomic Analysis of Patients Undergoing Bariatric SurgeryNot yet recruitingNCT06787807Not applicable1 country
- Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary ObstructionEnrolling by invitationNCT06671418Phase 31 country
- Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNARecruitingNCT04183712Phase 21 country
- NGS in Gallbladder Cancer and Response to TreatmentRecruitingNCT054043471 country